文章摘要
赵 倩,张景丽,程思思,蒋秀芳,任常军.重组人干扰素α-2b注射液雾化吸入与重组人干扰素α-2b喷雾剂局部外用喷咽部治疗手足口病的疗效[J].,2019,19(8):1559-1562
重组人干扰素α-2b注射液雾化吸入与重组人干扰素α-2b喷雾剂局部外用喷咽部治疗手足口病的疗效
Efficacy of Nebulization Inhalation of Interferon α-2b Injection Atomization Inhalation and Recombinant Human Interferon α-2b Spray in the Local External Use of the Sprayed Pharynx in the Treatment of Hand Foot and Mouth Disease
投稿时间:2018-10-23  修订日期:2018-11-18
DOI:10.13241/j.cnki.pmb.2019.08.036
中文关键词: 手足口病  重组人干扰素α-2b  雾化吸入  喷雾剂
英文关键词: Hand foot and mouth disease  Recombinant human interferon α-2b  Atomization inhalation  Spray
基金项目:河北省医学科学研究重点项目(ZL20140054)
作者单位
赵 倩 河北医科大学第一医院儿科 河北 石家庄030000 
张景丽 河北省儿童医院呼吸科 河北 石家庄030000 
程思思 河北医科大学第一医院儿科 河北 石家庄030000 
蒋秀芳 河北医科大学第一医院儿科 河北 石家庄030000 
任常军 河北医科大学第一医院儿科 河北 石家庄030000 
摘要点击次数: 579
全文下载次数: 251
中文摘要:
      摘要 目的:探讨重组人干扰素α-2b注射液雾化吸入与重组人干扰素α-2b喷雾剂局部外用喷咽部治疗手足口病的疗效。方法:选择2016年1月至2017年12月就诊于河北省儿童医院的160例手足口病患儿作为研究对象,通过随机数表法分为对照组和试验组,每组80例。2组均给予手足口病常规治疗措施,对照组在此常规治疗基础上给予重组人干扰素α-2b喷雾剂治疗,喷涂于咽喉部,每次1喷,3次/d,试验组在常规治疗基础上,给予重组人干扰素α-2b注射液10万U(kg?次)加入生理盐水2 mL中进行雾化吸入治疗,2次/d;2组疗程均为3~5d。比较2组临床疗效、临床症状改善时间、血清指标及不良反应。结果:治疗后,试验组和对照组临床疗效总有效率分别为91.25%(73/80)和76.25%(61/80),差异具有统计学意义(P<0.05);试验组和对照组体温正常时间分别为(2.78±0.42)和(4.13±0.58)d,皮疹消退时间分别为(3.53±0.55)和(5.05±0.63)d,口腔溃疡愈合时间分别为(3.35±0.58)和(4.80±0.58)d,正常进食时间分别为(3.91±0.58)和(4.98±0.50)d,住院时间分别为(5.91±0.92)和(8.14±0.81)d,差异均具有统计学意义(P<0.05);治疗后,试验组和对照组血清淀粉样蛋白A(SAA)分别为(133.43±25.74)和(178.53±26.96)mg?L-1,C反应蛋白(CRP)分别为(4.75±0.71)和(8.54±1.29)mg?L-1,差异均具有统计学意义(P<0.05);治疗期间,对照组出现恶心呕吐5例,皮疹1例,试验组出现7例恶心呕吐,2例腹泻,2组不良反应总发生率分别为7.50(6/80)、11.25%(9/80),比较无显著差异(P>0.05)。结论:在手足口病患儿中使用重组人干扰素α-2b注射液雾化吸入效果显著,可有效促进疾病缓解,且用药安全性高,值得应用推广。
英文摘要:
      ABSTRACT Objective: To study the efficacy of nebulization inhalation of interferon α-2b injection atomization inhalation and recombinant human interferon α-2b sprayin the local external use of the sprayed pharynx in the treatment of hand foot and mouth disease. Methods: 160 children of hand foot and mouth disease who received therapy from January 2016 to December 2017 in the Hebei children's Hospital were selected as research objects, according to random number table, those patients were divided into the control group group and the treatment group group, 80 cases in each group. he 2 groups were given routine treatment for hand foot and mouth disease, on the basis of the routine treatment, the control group was treated with recombinant human interferon α-2b spray, spraying on the throat, one spraying each time, and 3 times/d, on the basis of routine treatment, the treatment group was given interferon α-2b injection 10 million U (kg?time) into the saline 2 mL for nebulization and inhalation, 2 times/d; the 2 groups were all 3~5d. The clinical curative effect, clinical symptom improvement time, serum index and adverse reaction of two groups were compared. Results: After treatment, the total effective effective rate of the treatment group and the control group was 91.25% (73/80) and 76.25% (61/80) respectively, the differences was statistically significant(P<0.05); the temperature normal time of the treatment group and the control group was(2.78±0.42)and(4.13±0.58)d respectively, the rash subsided time was(3.53±0.55)and(5.05±0.63)d respectively, the oral ulcer healing time(3.35±0.58)and(4.80±0.58)d respectively, the normal feeding time was(3.91±0.58) and(4.98±0.50)d, the hospitalization time was(5.91±0.92)and(8.14±0.81)d, the differences was statistically significant(P<0.05); after treatment, the serum amyloid A (SAA) in the treatment group and the control group was(133.43±25.74)and(178.53±26.96)mg?L-1 respectively, the C reactive protein (CRP) was(4.75±0.71)and(8.54±1.29)mg?L-1 respectively, the differences was statistically significant(P<0.05); during the treatment period, there were 5 cases of nausea and vomiting and 1 cases of rash in the control group, 7 cases of nausea and vomiting and 2 cases of diarrhea in the treatment group, the total incidence of adverse reactions in the 2 groups were 7.50 (6/80) and 11.25% (9/80), respectively, and there was no significant difference(P>0.05). Conclusion: Interferon α-2b injection atomization inhalation is well for children with hand foot and mouth disease, which can effectively promote the remission of the disease, and the safety of drug use is high, and it is worthy of application and promotion.
查看全文   查看/发表评论  下载PDF阅读器
关闭